US 11,667,909 B2
Diagnosis of prostate cancer
Heather R. Sanders, Winchester, CA (US)
Assigned to Quest Diagnostics Investments LLC, Secaucus, NJ (US)
Filed by Quest Diagnostics Investments LLC, Secaucus, NJ (US)
Filed on May 29, 2020, as Appl. No. 16/887,079.
Application 16/887,079 is a continuation of application No. 15/952,452, filed on Apr. 13, 2018, granted, now 10,669,536.
Application 15/952,452 is a continuation of application No. 15/593,921, filed on May 12, 2017, granted, now 9,963,695.
Application 15/593,921 is a continuation of application No. 13/997,868, granted, now 9,663,781, previously published as PCT/US2011/067880, filed on Dec. 29, 2011.
Claims priority of provisional application 61/428,750, filed on Dec. 30, 2010.
Prior Publication US 2020/0354712 A1, Nov. 12, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. C12P 19/34 (2006.01); C12N 15/10 (2006.01); C12Q 1/6806 (2018.01); C12Q 1/6886 (2018.01)
CPC C12N 15/1017 (2013.01) [C12Q 1/6806 (2013.01); C12Q 1/6886 (2013.01); C12Q 2600/158 (2013.01)] 17 Claims
 
1. A detection method comprising:
generating a soluble urine concentrate from a soluble urine fraction by ultrafiltration, wherein the volume of soluble urine concentrate is reduced at least 50% from the original urine volume; and
contacting the soluble urine concentrate with at least one set of primer pairs and at least one probe to detect the amount of RNA from each of heat shock 60 kDa protein 1 (HSPD1), inosine monophosphate dehydrogenase 2 (IMPDH2), PDZ and LEVI domain 5 (PDLIM5), and UDP-N-acetylglucosamine pyrophosphorylase 1 (UAP1), wherein the at least one probe is labeled with a detectable label.